Statera Biopharma, Inc. · OTC:STAB
Statera Biopharma — Benzinga Conference 2021
12 slides from Statera Biopharma's conference presentation, Sep 29, 2021
Slide 1: Restoring Immune Health
(NASDAQ: STAB) Restoring Immune Health September 2021 Corporate Presentation 1 September 2021
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve risks and uncertainties. All statements other than statements of current or historical fact contained in this presentation, including statements regarding the expected clinical development timeline for the
Slide 3: History
HISTORY • Legacy Cleveland Biolabs spun off • Closing of merger between legacy from The Cleveland Clinic in 2003 Cleveland BioLabs (NASDAQ: CBLI) and • Legacy Cytocom spun off from formerly private Cytocom on July 28, Immune Therapeutics in late 2014 2021 • Approach to drug development is • Treat mu
Slide 4: Restoring Immune Health
RESTORING IMMUNE HEALTH Statera Biopharma intends to become the leader in developing and commercializing therapies that help restore the immune system and keep it in homeostasis which we believe is safer and more effective. § Phase 3 Crohn’s Study with STAT-201 § Clinical Hematology Study with entol
Slide 5: Leadership Team
LEADERSHIP TEAM Michael Handley President & CEO Taunia Markvicka, Pharm.D. Peter Aronstam, Ph.D. Steve Wilson, Ph.D. Leadership Chief Financial Officer Global Head of Innovation Chief Operating Officer Cozette McAvoy, J.D. Clifford Selsky, M.D., Ph.D. Robert Buckheit, Ph.D. Chief Legal Officer & Chi
Slide 6: Rethinking Immunotherapies
RETHINKING IMMUNOTHERAPIES Developing immunotherapies that restore dysfunctional immune systems to a Our state of homeostasis evolutionarily designed to fight cancers, emerging viruses Approach and not result in autoimmune disease (overactive immune system) Horwitz et al., Rebalancing Immune Homeost
Slide 7: Pipeline Focus
PIPELINE FOCUS Initially targeting Autoimmune, Oncology and Hematology Autoimmune Oncology Hematology Acute Neutropenia & Crohn’s Disease Pancreatic Cancer Anemia (STAT-201) (STAT-401) (Entolimod™) Chronic Neutropenia & Multiple Sclerosis Hepatocellular Cancer Anemia (STAT-203) (STAT-402) (GP532) 7
Slide 8: Development Pipeline
DEVELOPMENT PIPELINE Lead Programs Designation Indication Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Optimization STAT-201 Crohn’s Disease STAT-200 Program STAT-202 Fibromyalgia noroxymorphone-n-substituted- methyl cyclopropyl STAT-203 MS STAT-205 COVID STAT-200 Development Autoimmune & Emer
Slide 9: Intellectual Property
INTELLECTUAL PROPERTY Programs Family Principal Patent #s Title STAT-0010 8,633,150 Method for Inducing a Sustained Immune Response 10,111,870, 10,695,343, Application STAT-200 Patents STAT-0011 Method for Inducing a Sustained Immune Response 16/898,557 noroxymorphone-n-substituted- methyl cycloprop
Slide 10: STAT-201: Crohn's Disease Opportunity
STAT-201: CROHN’S DISEASE OPPORTUNITY Position: Oral therapy with long-term safety at low doses for early intervention to maintain prolonged remission through mucosal healing leading to improved outcomes Sequential Therapies for Crohn’s Disease Phase 2 study supporting proof of concept and safety ST
Slide 11: STAT-401: Pancreatic Cancer Opportunity
STAT-401: PANCREATIC CANCER OPPORTUNITY Position: Adjunct to standard of care to prolong survival by stabilizing disease or slowing progression Survival of Metastatic Pancreatic Cancer is Improved with STAT-401 20 19 Phase 1b/2 PK and safety study expected to 18 initiate 1H22 16 Clinical benefit res
Slide 12: 2021-2022 Potential Catalysts
2021-2022 POTENTIAL CATALYSTS Potential Catalysts *Near Term (12-24 Months) *Long Term (>24 months) • Phase 3 Crohn’s Study with STAT-201 expected 4Q21 • Expect to begin patient enrollment in 4Q21 • Clinical Hematology Study with Entolimod • Phase 2 COVID Study with STAT-205 • Multiple Sclerosis Exp